X-Vax Technology
Biotechnology company developing a vaccine to prevent and treat herpes simplex virus (HSV) infections, addressing a significant unmet medical need affecting billions of people worldwide.
Website
https://www.xvax.comLocation
New York, New York, USA
Founded
2015
Investors
1
Categories
vaccines, infectious-disease, biotech, herpes
Notes
X-Vax Technology is a biotechnology company developing a vaccine to prevent and treat herpes simplex virus (HSV) infections. The company is headquartered in New York, New York.
Herpes simplex virus affects billions of people worldwide, causing:
- Oral herpes (HSV-1)
- Genital herpes (HSV-2)
- Neonatal herpes (life-threatening in newborns)
- Increased HIV transmission risk
Despite the enormous disease burden, there is currently no approved vaccine for HSV. X-Vax is working to develop both prophylactic (preventive) and therapeutic vaccines for herpes.
Team
- William Halford, Ph.D. - Scientific Founder (deceased)
- Leadership team information not fully disclosed
Additional Research Findings
- Herpes simplex virus vaccine development
- Both HSV-1 and HSV-2 targets
- Prophylactic and therapeutic approaches
- Significant unmet medical need
- New York, New York headquarters
- Founded in 2015
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |